World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
86
Citations
24826
World Ranking
14225
National Ranking
73

Overview

Klaus Podar is affiliated with the Karl Landsteiner University of Health Sciences in Austria. Their research spans the fields of Medicine and Biochemistry, Genetics and Molecular Biology, with a focus on Molecular Biology, Hematology, and Oncology. This expertise is reflected across numerous publications centered on cancer and blood disorders.

The main topics of their work include:

  • Multiple Myeloma Research and Treatments
  • Protein Degradation and Inhibitors
  • CAR-T cell therapy research
  • Cancer Treatment and Pharmacology
  • Ubiquitin and proteasome pathways
  • Bone health and treatments
  • RNA Interference and Gene Delivery

Among their recent papers are the following:

  • Selinexor for the treatment of multiple myeloma, 2020, Expert Opinion on Pharmacotherapy
  • Relapsed/Refractory Multiple Myeloma in 2020/2021 and Beyond, 2021, Cancers
  • The Role of AP-1 Transcription Factors in Plasma Cell Biology and Multiple Myeloma Pathophysiology, 2021, Cancers

They also contributed to research published in other venues such as PubMed and Clinical Cancer Research, with papers like BindingDB Entry 50022503: A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase (2025) and Tissue Hypoxia and Alterations in Microvascular Architecture Predict Glioblastoma Recurrence in Humans (2020).

Klaus Podar frequently publishes in journals such as:

  • Cancers
  • Blood
  • Clinical Lymphoma Myeloma & Leukemia
  • Expert Opinion on Pharmacotherapy
  • Leukemia

Their collaborations include multiple co-authors with whom they have published extensively. Frequent co-authors include:

  • Sonia Vallet
  • Judith Lind
  • Martin Pecherstorfer
  • Osman Aksoy
  • Martin Sattler

Best Publications

  • Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma.

    Faith E. Davies;Noopur Raje;Noopur Raje;Noopur Raje;Teru Hideshima;Teru Hideshima;Teru Hideshima;Suzanne Lentzsch;Suzanne Lentzsch;Suzanne Lentzsch

  • Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications.

    D Gupta;S P Treon;Y Shima;T Hideshima

  • A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib

    Dharminder Chauhan;Laurence Catley;Guilan Li;Klaus Podar

  • Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.

    Teru Hideshima;Constantine Mitsiades;Masaharu Akiyama;Toshiaki Hayashi

  • Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells

    Teru Hideshima;Laurence Catley;Hiroshi Yasui;Kenji Ishitsuka

  • Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration

    Klaus Podar;Yu-Tzu Tai;Faith E. Davies;Suzanne Lentzsch

  • Oral selinexor-dexamethasone for triple-class refractory multiple myeloma

    Ajai Chari;Dan T Vogl;Maria Gavriatopoulou;Ajay K Nooka

  • Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu

    Yu Tzu Tai;Myles Dillon;Weihua Song;Merav Leiba

  • Critical role for Gab2 in transformation by BCR/ABL

    Martin Sattler;M.Golam Mohi;Yuri B Pride;Laura R Quinnan

  • The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications.

    Klaus Podar;Kenneth C. Anderson

  • Bone marrow microenvironment and the identification of new targets for myeloma therapy.

    K Podar;D Chauhan;K C Anderson

  • Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application.

    Toshiaki Hayashi;Teru Hideshima;Masaharu Akiyama;Klaus Podar

  • Bortezomib induces canonical nuclear factor-κB activation in multiple myeloma cells

    Teru Hideshima;Hiroshi Ikeda;Dharminder Chauhan;Yutaka Okawa

  • Blockade of Hsp27 Overcomes Bortezomib/Proteasome Inhibitor PS-341 Resistance in Lymphoma Cells

    Dharminder Chauhan;Guilan Li;Reshma Shringarpure;Klaus Podar

  • Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment.

    Yu-Tzu Tai;Xian-Feng Li;Iris Breitkreutz;Weihua Song

  • Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma.

    Noopur Raje;Shaji Kumar;Shaji Kumar;Teru Hideshima;Kenji Ishitsuka

  • Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target.

    Dharminder Chauhan;Ajita V. Singh;Mohan Brahmandam;Ruben Carrasco

  • A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase.

    Martin Sattler;Yuri B. Pride;Patrick Chi-Chung Ma;Jessica L. Gramlich

  • Novel therapies targeting the myeloma cell and its bone marrow microenvironment.

    Teru Hideshima;Dharminder Chauhan;Klaus Podar;Robert L Schlossman

  • Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo.

    S Lentzsch;R LeBlanc;K Podar;F Davies

Frequent Co-Authors

Teru Hideshima
Teru Hideshima Harvard University
Dharminder Chauhan
Dharminder Chauhan Harvard University
Kenneth C. Anderson
Kenneth C. Anderson Harvard University
Yu-Tzu Tai
Yu-Tzu Tai Harvard University
Paul G. Richardson
Paul G. Richardson Harvard University
Nikhil C. Munshi
Nikhil C. Munshi Harvard University
Noopur Raje
Noopur Raje Harvard University
Martin Sattler
Martin Sattler Harvard University
Constantine S. Mitsiades
Constantine S. Mitsiades Harvard University
Robert L. Schlossman
Robert L. Schlossman Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring medicine in the USA can open doors to a wide range of health-related careers. For those interested in getting started quickly, consider an lpn program no entrance exam. These programs offer a streamlined route into nursing by eliminating standardized test requirements, making them ideal for students seeking a fast entry into the workforce.

If your goals include medical management, an degree in healthcare administration builds leadership and organizational skills for health services roles. This is a valuable online option for those interested in running clinics, managing hospital departments, or leading health organizations.

For registered nurses aiming for advanced clinical roles, adn to fnp bridge programs allow professionals to become family nurse practitioners without starting from scratch. These bridge programs are flexible and support career advancement for working nurses.

Those passionate about nutrition and preventive health can pursue an online bs in nutrition. This degree is ideal for future dietitians, wellness specialists, or anyone seeking to promote healthy living through science-backed knowledge.

Best Scientists Citing Klaus Podar

Trending Scientists

Recently Published Articles